Through their association (AFPC
), French competitiveness clusters decided in 2021 to create the hi-France label
to strengthen their support for the search for private funding and investors to accompany the growth and internationalization of innovative companies.
According to the AFPC, the French Association of Competitiveness Clusters, “this national labeling process promotes the scientific foundation and market potential for innovations developed in France by calling on the combined expertise of technology and market experts from the public and private sectors.”
Earning the hi-France label
involves a multi-stage process, from submitting the application to obtaining approval by the national labeling committee.
was one of the 13 companies selected by the national labeling committee in June 2022.
As pointed out by AFPC, “the label is a symbol of recognition for the excellence of innovative French companies in which it makes sense to invest. It offers investors a guarantee of the best investment opportunities and facilitates the search for private funding.
The label was awarded to Acobiom by the Medicen
competitiveness cluster, notably thanks to the benefits provided by the company’s GemciTest®
, a predictive therapeutic response diagnostic that identifies the pancreatic cancer patients most likely to benefit from first-line treatment based on gemcitabine, alone or in combination with other drugs.
According to the cluster, “Acobiom offers an innovative, non-invasive in vitro blood diagnostic to predict patient response to a given therapy. With GemciTest, Acobiom offers the first diagnostic tool for predicting patient response in pancreatic cancer treatment.
This label represents recognition for the entire Acobiom team, in particular its technological expertise combining genomics, transcriptomics, bioinformatics, and data science
, as well as its innovative approach based on real-life data to develop a new generation of diagnostics
for precision and personalized medicine to prescribe the most appropriate and effective therapy for each patient.